LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Elastase-mediated cleavage of cyclin E generates low molecular weight cyclin E (LMW-E) isoforms exhibiting enhanced CDK2-associated kinase activity and resistance to inhibition by CDK inhibitors p21 and p27. Approximately 27% of breast cancers express high LMW-E protein levels, which significantly c...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS Genetics |
| Online Access: | http://europepmc.org/articles/PMC3315462?pdf=render |
| _version_ | 1828734815912853504 |
|---|---|
| author | MyLinh T Duong Said Akli Caimiao Wei Hannah F Wingate Wenbin Liu Yiling Lu Min Yi Gordon B Mills Kelly K Hunt Khandan Keyomarsi |
| author_facet | MyLinh T Duong Said Akli Caimiao Wei Hannah F Wingate Wenbin Liu Yiling Lu Min Yi Gordon B Mills Kelly K Hunt Khandan Keyomarsi |
| author_sort | MyLinh T Duong |
| collection | DOAJ |
| description | Elastase-mediated cleavage of cyclin E generates low molecular weight cyclin E (LMW-E) isoforms exhibiting enhanced CDK2-associated kinase activity and resistance to inhibition by CDK inhibitors p21 and p27. Approximately 27% of breast cancers express high LMW-E protein levels, which significantly correlates with poor survival. The objective of this study was to identify the signaling pathway(s) deregulated by LMW-E expression in breast cancer patients and to identify pharmaceutical agents to effectively target this pathway. Ectopic LMW-E expression in nontumorigenic human mammary epithelial cells (hMECs) was sufficient to generate xenografts with greater tumorigenic potential than full-length cyclin E, and the tumorigenicity was augmented by in vivo passaging. However, cyclin E mutants unable to interact with CDK2 protected hMECs from tumor development. When hMECs were cultured on Matrigel, LMW-E mediated aberrant acinar morphogenesis, including enlargement of acinar structures and formation of multi-acinar complexes, as denoted by reduced BIM and elevated Ki67 expression. Similarly, inducible expression of LMW-E in transgenic mice generated hyper-proliferative terminal end buds resulting in enhanced mammary tumor development. Reverse-phase protein array assay of 276 breast tumor patient samples and cells cultured on monolayer and in three-dimensional Matrigel demonstrated that, in terms of protein expression profile, hMECs cultured in Matrigel more closely resembled patient tissues than did cells cultured on monolayer. Additionally, the b-Raf-ERK1/2-mTOR pathway was activated in LMW-E-expressing patient samples, and activation of this pathway was associated with poor disease-specific survival. Combination treatment using roscovitine (CDK inhibitor) plus either rapamycin (mTOR inhibitor) or sorafenib (a pan kinase inhibitor targeting b-Raf) effectively prevented aberrant acinar formation in LMW-E-expressing cells by inducing G1/S cell cycle arrest. LMW-E requires CDK2-associated kinase activity to induce mammary tumor formation by disrupting acinar development. The b-Raf-ERK1/2-mTOR signaling pathway is aberrantly activated in breast cancer and can be suppressed by combination treatment with roscovitine plus either rapamycin or sorafenib. |
| first_indexed | 2024-04-12T22:55:47Z |
| format | Article |
| id | doaj.art-79d820183631449dad12d3d66edf59b5 |
| institution | Directory Open Access Journal |
| issn | 1553-7390 1553-7404 |
| language | English |
| last_indexed | 2024-04-12T22:55:47Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Genetics |
| spelling | doaj.art-79d820183631449dad12d3d66edf59b52022-12-22T03:13:12ZengPublic Library of Science (PLoS)PLoS Genetics1553-73901553-74042012-01-0183e100253810.1371/journal.pgen.1002538LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.MyLinh T DuongSaid AkliCaimiao WeiHannah F WingateWenbin LiuYiling LuMin YiGordon B MillsKelly K HuntKhandan KeyomarsiElastase-mediated cleavage of cyclin E generates low molecular weight cyclin E (LMW-E) isoforms exhibiting enhanced CDK2-associated kinase activity and resistance to inhibition by CDK inhibitors p21 and p27. Approximately 27% of breast cancers express high LMW-E protein levels, which significantly correlates with poor survival. The objective of this study was to identify the signaling pathway(s) deregulated by LMW-E expression in breast cancer patients and to identify pharmaceutical agents to effectively target this pathway. Ectopic LMW-E expression in nontumorigenic human mammary epithelial cells (hMECs) was sufficient to generate xenografts with greater tumorigenic potential than full-length cyclin E, and the tumorigenicity was augmented by in vivo passaging. However, cyclin E mutants unable to interact with CDK2 protected hMECs from tumor development. When hMECs were cultured on Matrigel, LMW-E mediated aberrant acinar morphogenesis, including enlargement of acinar structures and formation of multi-acinar complexes, as denoted by reduced BIM and elevated Ki67 expression. Similarly, inducible expression of LMW-E in transgenic mice generated hyper-proliferative terminal end buds resulting in enhanced mammary tumor development. Reverse-phase protein array assay of 276 breast tumor patient samples and cells cultured on monolayer and in three-dimensional Matrigel demonstrated that, in terms of protein expression profile, hMECs cultured in Matrigel more closely resembled patient tissues than did cells cultured on monolayer. Additionally, the b-Raf-ERK1/2-mTOR pathway was activated in LMW-E-expressing patient samples, and activation of this pathway was associated with poor disease-specific survival. Combination treatment using roscovitine (CDK inhibitor) plus either rapamycin (mTOR inhibitor) or sorafenib (a pan kinase inhibitor targeting b-Raf) effectively prevented aberrant acinar formation in LMW-E-expressing cells by inducing G1/S cell cycle arrest. LMW-E requires CDK2-associated kinase activity to induce mammary tumor formation by disrupting acinar development. The b-Raf-ERK1/2-mTOR signaling pathway is aberrantly activated in breast cancer and can be suppressed by combination treatment with roscovitine plus either rapamycin or sorafenib.http://europepmc.org/articles/PMC3315462?pdf=render |
| spellingShingle | MyLinh T Duong Said Akli Caimiao Wei Hannah F Wingate Wenbin Liu Yiling Lu Min Yi Gordon B Mills Kelly K Hunt Khandan Keyomarsi LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genetics |
| title | LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. |
| title_full | LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. |
| title_fullStr | LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. |
| title_full_unstemmed | LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. |
| title_short | LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. |
| title_sort | lmw e cdk2 deregulates acinar morphogenesis induces tumorigenesis and associates with the activated b raf erk1 2 mtor pathway in breast cancer patients |
| url | http://europepmc.org/articles/PMC3315462?pdf=render |
| work_keys_str_mv | AT mylinhtduong lmwecdk2deregulatesacinarmorphogenesisinducestumorigenesisandassociateswiththeactivatedbraferk12mtorpathwayinbreastcancerpatients AT saidakli lmwecdk2deregulatesacinarmorphogenesisinducestumorigenesisandassociateswiththeactivatedbraferk12mtorpathwayinbreastcancerpatients AT caimiaowei lmwecdk2deregulatesacinarmorphogenesisinducestumorigenesisandassociateswiththeactivatedbraferk12mtorpathwayinbreastcancerpatients AT hannahfwingate lmwecdk2deregulatesacinarmorphogenesisinducestumorigenesisandassociateswiththeactivatedbraferk12mtorpathwayinbreastcancerpatients AT wenbinliu lmwecdk2deregulatesacinarmorphogenesisinducestumorigenesisandassociateswiththeactivatedbraferk12mtorpathwayinbreastcancerpatients AT yilinglu lmwecdk2deregulatesacinarmorphogenesisinducestumorigenesisandassociateswiththeactivatedbraferk12mtorpathwayinbreastcancerpatients AT minyi lmwecdk2deregulatesacinarmorphogenesisinducestumorigenesisandassociateswiththeactivatedbraferk12mtorpathwayinbreastcancerpatients AT gordonbmills lmwecdk2deregulatesacinarmorphogenesisinducestumorigenesisandassociateswiththeactivatedbraferk12mtorpathwayinbreastcancerpatients AT kellykhunt lmwecdk2deregulatesacinarmorphogenesisinducestumorigenesisandassociateswiththeactivatedbraferk12mtorpathwayinbreastcancerpatients AT khandankeyomarsi lmwecdk2deregulatesacinarmorphogenesisinducestumorigenesisandassociateswiththeactivatedbraferk12mtorpathwayinbreastcancerpatients |